Business Context and Reporting Period
This Form 8-K was filed by OncoGenex Pharmaceuticals, Inc. on May 15, 2017. The filing serves to announce the company's financial results for the first quarter of 2017. The registrant is incorporated in Delaware and maintains its principal executive offices in Bothell, Washington.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a notification that a press release containing these details has been issued and is attached as Exhibit 99.1. Consequently, no financial metrics can be extracted from the text of this 8-K alone.
Material Changes
The filing does not detail specific material changes versus the prior comparable period. It references the issuance of a press release regarding Q1 2017 results but does not summarize the comparative performance within the body of this report.
Guidance, Outlook, and Risks
The text does not provide management commentary, forward-looking guidance, specific risk factors, or details on contingencies. It explicitly states that the information in Item 2.02 and Exhibit 99.1 is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor incorporated by reference except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (the press release dated May 15, 2017) for actual Q1 2017 financial figures.
- Verify the company's current name, as the metadata header mentions "ACHIEVE LIFE SCIENCES, INC." while the filing body identifies the registrant as "ONCOGENEX PHARMACEUTICALS, INC."
- Confirm the status of the company's cash position and runway, as these are critical for a biopharmaceutical firm but are not listed in this summary document.
- Check for any subsequent filings that may incorporate the press release by reference.